1. Scrip
  2. >>New Products

J&J's Quad HIV Combo Likely To Pass CHMP; EU Market Uptake Is Trickier

 
• By Lucie Ellis-Taitt

Johnson & Johnson's quadruple HIV combination is likely to win a positive recommendation for approval in Europe this week – but clever positioning will be required to secure strong uptake for the combination considering its late entry onto a competitive market place.

HIV virus
Janssen's Quad HIV Treatment Must Cleverly Compete With Marketed Options And Incoming Therapies

Johnson & Johnson's HIV combination therapy, darunavir/emtricitabine/cobicistat/tenofovir alafenamide, is likely to get a positive recommendation this week from the European Medicines Agency's scientific committee, the CHMP – a vote that will set up the product for its first approval worldwide.

However, Janssen Pharmaceutical Co. (J&J's pharma business) will need to focus on positioning D/C/F/TAF as a second-line treatment alternative if...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By Kevin Grogan

Lynkuet will compete with Astellas's Veozah/Veoza

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 
• By Jessica Merrill

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

More from Scrip

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 
• By Jessica Merrill

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.